3-dimensional large capacity cell encapsulation device assembly

• US 9,526,880 B2
• Filed: 03/07/2014
• Issued: 12/27/2016
• Est. Priority Date: 03/07/2013
• Status: Active Grant

• Current Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Original Assignee: Viacyte Incorporated (Vertex Pharmaceuticals Incorporated)
• Inventors: Zamarripa, Mario, So, Vincent, Martinson, Laura, Green, Chad, Scott, Michael
• Primary Examiner(s): JOHNSON, KARA D
• Application Number:
  US14/201,630
• Publication Number:
  US 20140257515A1
• Time in Patent Office: 1,026 Days
• US Class Current: 1/1
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61M 2202/09 Body tissue
• CPC Class Codes: A61M 2205/04 implanted
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

Disclosed herein are implantable 3-dimensional large capacity device assemblies, specifically, large capacity device assemblies for encapsulating pancreatic progenitor cells for treatment of diabetes.

Claims

1. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees.

2. The assembly of claim 1, wherein the assembly comprises a semi-permeable membrane.

3. The assembly of claim 1, wherein the assembly comprises at least three, four, five, six, seven, eight or more cell chambers.

4. The assembly of claim 1, further comprising at least one loading port.

5. The assembly of claim 1, further comprising definitive endoderm-lineage cells.

6. The assembly of claim 1, further comprising human immature beta cells.

7. The assembly of claim 1, further comprising a cell chamber matrix having a plurality of interconnected cavities or pores to disperse the living cells and to improve oxygen distribution inside the cell chamber.

8. The assembly of claim 7, wherein the interconnected cavities have different cavity dimensions.

9. The assembly of claim 7, wherein the matrix is polydimethylsiloxane (PDMS), polydimethylsiloxane mono acrylate, and polydimethylsiloxane monomethacrylate.

10. The assembly of claim 7, wherein the matrix is a silicone elastomer.

11. The assembly of claim 7, wherein the matrix is a polydimethylsiloxane (PDMS).

12. The assembly of claim 1, wherein the cell chambers are separated by about 20 degrees.

13. The assembly of claim 1, wherein the cell chambers are separated by about 40 degrees.

16. The assembly of claim 1, further comprising a partition seal within the cell chamber.

14. A encapsulating assembly, said assembly comprising at least two cell chambers, a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees, further comprising human endocrine precursor cells.

15. The assembly of claim 14, further comprising human pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.

17. A cell encapsulating assembly, said assembly comprising at least two cell chambers and a cell-free region along the longest axis separating the cell chambers, wherein the cell-free region is bent 5 to 175 degrees and further comprising pancreatic and duodenal homeobox gene 1 (PDX1)-positive pancreatic progenitor cells.